{
  "id": 20617609,
  "title": "Biogen Reports Two-Year Data Showing Diranersen Slows Early Alzheimer's Decline",
  "url": "https://urgent.news/2026/11/18/biogen-reports-two-year-data-showing-diranersen-slows-early",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-18T15:40:12.000Z",
  "source": {
    "name": "Benzinga",
    "slug": "benzinga",
    "url": "https://www.benzinga.com/news/health-care/26/11/63392415/biogen-reports-two-year-data-showing-diranersen-slows-early-alzheimers-decline"
  },
  "original_language": "en",
  "account": null,
  "summary": "Biogen Inc. (NASDAQ:BIIB) announced Tuesday that its investigational therapy diranersen slowed clinical decline at two years in people living with early Alzheimer’s disease, according to new Phase 2 CELIA study data. Presenters shared the Week 96 findings at the Clinical Trials on Alzheimer’s Disease (CTAD) 2026 conference. The results showed that diranersen, an antisense oligonucleotide (ASO)…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}